Oxford Asset Management’s Clearside Biomedical CLSD Stock Holding History

Oxford Asset Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$21K	Sell	819 -7,967	-91%	-$295K	﹤0.01%	184
2019 Q4	$382K	Buy	+8,786	New	+$185K	0.01%	1352

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Oxford Asset Management's CLSD Position: Q1 2020 in Review

Oxford Asset Management reduced its Clearside Biomedical (CLSD) stake by 91% in Q1 2020, selling an estimated $295K and leaving 819 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #184.

Oxford Asset Management first reported a position in CLSD in Q4 2019 and has held it in 2 quarters since. The position peaked at $382K in Q4 2019. 43 funds tracked by Wall St. Rank hold CLSD as of Q1 2020.

Oxford Asset Management held 819 shares of Clearside Biomedical worth $21K as of Q1 2020.
Oxford Asset Management sold 7,967 Clearside Biomedical shares in Q1 2020, an estimated $295K.
Clearside Biomedical made up ﹤0.01% of Oxford Asset Management's portfolio in Q1 2020, its #184 holding.
Oxford Asset Management first reported a position in Clearside Biomedical in Q4 2019 and has held it in 2 quarters since.
Oxford Asset Management's Clearside Biomedical position peaked at $382K in Q4 2019.
43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.